Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTFIPZ)

Drug Name
2-Hexadecynoic acid Drug Info
Synonyms 2-Hexadecynoic acid; hexadec-2-ynoic acid; 2834-03-9; 2-Hexadecynoate; N-2-Hexadecynoic acid; AC1L45K9; SCHEMBL2818253; CTK4G1266; DTXSID00182577; MECFGCCEVOFCNS-UHFFFAOYSA-N; NSC289580; LMFA01030494
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
151047
CAS Number
CAS 2834-03-9
TTD Drug ID
DMTFIPZ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Approved Drug(s)
Preclinical Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [2]
Morin DM2OGZ5 Discovery agent N.A. Investigative [2]
biochanin A DM0HPWY Discovery agent N.A. Investigative [2]
3,7,3',4'-TETRAHYDROXYFLAVONE DMES906 Discovery agent N.A. Investigative [2]
(-)-CATECHINGALLATE DMZOGSK Discovery agent N.A. Investigative [2]
GALLOCATECHIN GALLATE DMX2084 Discovery agent N.A. Investigative [2]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Targeting Fatty acid synthase (FASN)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cerulenin DM6N4PR Weight loss MG43.5 Approved [3]
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [2]
TVB-2640 DM19GUH Astrocytoma 2A00.0Y Phase 2 [4]
TVB-2640 DMP30SA Non-alcoholic fatty liver disease DB92 Phase 2 [5]
FAS1 DMAX2EW Fungal infection 1F29-1F2F Preclinical [6]
FSA2 DMLNRCI Fungal infection 1F29-1F2F Preclinical [6]
Morin DM2OGZ5 Discovery agent N.A. Investigative [2]
biochanin A DM0HPWY Discovery agent N.A. Investigative [2]
3,7,3',4'-TETRAHYDROXYFLAVONE DMES906 Discovery agent N.A. Investigative [2]
(-)-CATECHINGALLATE DMZOGSK Discovery agent N.A. Investigative [2]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [2]
Chrysin DM7V2LG Discovery agent N.A. Investigative [2]
Kaempferol DMHEMUB Discovery agent N.A. Investigative [2]
Morin DM2OGZ5 Discovery agent N.A. Investigative [2]
3,7,3',4'-TETRAHYDROXYFLAVONE DMES906 Discovery agent N.A. Investigative [2]
(-)-CATECHINGALLATE DMZOGSK Discovery agent N.A. Investigative [2]
GALLOCATECHIN GALLATE DMX2084 Discovery agent N.A. Investigative [2]
ISORHAMNETIN DMQ4Z6E Discovery agent N.A. Investigative [2]
NADPH DM75Q34 Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 9 Drug(s)
Drug(s) Targeting Bacterial Fatty acid synthetase I (Bact inhA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Isoniazid DM5JVS3 Tuberculosis 1B10-1B1Z Approved [8]
Pyrazinamide DM4IF32 Mycobacterium infection 1B10-1B21 Approved [9]
Ethionamide DM8K3EI Tuberculosis 1B10-1B1Z Approved [10]
Prothionamide DMX0EZJ Tuberculosis 1B10-1B1Z Approved [10]
AFN-1720 DM6AJKC Bacterial infection 1A00-1C4Z Phase 2 [11]
MMV00/0053 DMF27BS Malaria 1F40-1F45 Terminated [12]
Nicotinamide-Adenine-Dinucleotide DM9LRKB N. A. N. A. Investigative [13]
Beta-D-Glucose DM5IHYP Discovery agent N.A. Investigative [13]
4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole DMX681M Discovery agent N.A. Investigative [13]
Indole Naphthyridinone DMB4ZNW Discovery agent N.A. Investigative [13]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial Fatty acid synthetase I (Bact inhA) TTVTX4N INHA_MYCTU Inhibitor [1]
Fatty acid synthase (FASN) TT7AOUD FAS_HUMAN Inhibitor [1]
Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ) TTHPFTS Q965D7_PLAFA Inhibitor [1]
Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG) TTBE4IR Q965D6_PLAFA Inhibitor [1]

References

1 2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections. Bioorg Med Chem. 2010 Nov 1;18(21):7475-85.
2 Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
3 Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro. J Cell Mol Med. 2010 Apr;14(4):982-91.
4 Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation. ACS Med Chem Lett. 2013 January 10; 4(1): 113-117.
5 Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities. Hepatology. 2020 Jul;72(1):103-118.
6 Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
7 Functional characterization of beta-ketoacyl-ACP reductase (FabG) from Plasmodium falciparum. Biochem Biophys Res Commun. 2003 Mar 28;303(1):387-92.
8 Diversity in enoyl-acyl carrier protein reductases. Cell Mol Life Sci. 2009 May;66(9):1507-17.
9 Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med. 2000 Sep;6(9):1043-7.
10 Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med. 2007 Jan 22;204(1):73-8.
11 Affinium Pharmaceuticals Announces the Initiation of a Phase 1 Intravenous Clinical Trial of a New Antibiotic Prodrug, and the Closing of a Follow-on Financing Round. PR Newswire Sep. 4, 2013 10:16 PM.
12 SAR and pharmacophore models for the rhodanine inhibitors of Plasmodium falciparum enoyl-acyl carrier protein reductase. IUBMB Life. 2010 Mar;62(3):204-13.
13 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.